Patient ownership of primary biliary cholangitis long-term management

被引:3
|
作者
Leighton, Jessica [1 ]
Thain, Collette [2 ]
Mitchell-Thain, Robert [2 ]
Dyson, Jessica K. [1 ]
Jones, David E. [1 ]
机构
[1] Newcastle Univ, ICM, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[2] PBC Fdn, Edinburgh, Midlothian, Scotland
关键词
autoimmune liver disease; primary biliary cirrhosis;
D O I
10.1136/flgastro-2019-101324
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective Patient ownership of disease is vital in rare diseases like primary biliary cholangitis (PBC). This survey of UK members of the PBC foundation aimed to assess patients' perception of their disease management, focusing on key biomarkers and problematic symptoms. Design Registered PBC foundation members were surveyed on their experiences on their most recent clinic visit, covering the type of hospital and clinician and whether biochemical response and symptom burden were discussed, including who initiated these conversations. Respondents were also asked about their willingness to initiate these conversations. Results Across 633 respondents, 42% remembered discussing alkaline phosphatase, the key biochemical response measure, and the majority of discussions were initiated by the healthcare provider. 56% of respondents remembered discussing itch, a key PBC symptom. There was no distinction between the grade of healthcare professional, but both patients and clinicians were significantly more likely to discuss symptoms over disease progression. Reassuringly, 84% of respondents felt willing to initiate conversations about their illness, regardless of the grade of managing clinician. Conclusions This work lays a positive foundation for patient education and empowerment projects, likely to improve clinical outcomes. Key aspects of management (biochemical response to treatment and symptom burden) should be emphasised as topics of discussion to both patients and clinicians managing PBC. We suggest a simple cue card to prompt patient-led discussion.
引用
收藏
页码:370 / 373
页数:4
相关论文
共 50 条
  • [31] Primary sclerosing cholangitis treated by endoscopic biliary dilation: Review and long-term follow-up evaluation
    Johnson G.K.
    Saeian K.
    Geenen J.E.
    Current Gastroenterology Reports, 2006, 8 (2) : 147 - 155
  • [32] Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis
    Honda, Akira
    Tanaka, Atsushi
    Kaneko, Tetsuji
    Komori, Atsumasa
    Abe, Masanori
    Inao, Mie
    Namisaki, Tadashi
    Hashimoto, Naoaki
    Kawata, Kazuhito
    Takahashi, Atsushi
    Ninomiya, Masashi
    Kang, Jong-Hon
    Arakawa, Mie
    Yamagiwa, Satoshi
    Joshita, Satoru
    Umemura, Takeji
    Sato, Ken
    Kaneko, Akira
    Kikuchi, Kentaro
    Itakura, Jun
    Nomura, Takako
    Kakisaka, Keisuke
    Fujii, Hideki
    Kawada, Norifumi
    Takikawa, Yasuhiro
    Masaki, Tsutomu
    Ohira, Hiromasa
    Mochida, Satoshi
    Yoshiji, Hitoshi
    Iimuro, Satoshi
    Matsuzaki, Yasushi
    Takikawa, Hajime
    HEPATOLOGY, 2019, 70 (06) : 2035 - 2046
  • [33] LONG-TERM SAFETY OF SELADELPAR 10 MG WITH UP TO 5 YEARS OF TREATMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS
    Trivedi, Palak
    Gordon, Stuart
    Gulamhusein, Aliya
    Villamil, Alejandra
    Lawitz, Eric
    Vierling, John
    Londono, Maria Carlota
    Kremer, Andreas
    Bowlus, Christopher
    Proehl, Sarah
    Zhuo, Shuqiong
    Crittenden, Daria
    McWherter, Charles
    HEPATOLOGY, 2024, 80 : S1823 - S1824
  • [34] Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score
    Vinod S. Hegade
    Amardeep Khanna
    Lucy J. Walker
    Lin-Lee Wong
    Jessica K. Dyson
    David E. J. Jones
    Digestive Diseases and Sciences, 2016, 61 : 3037 - 3044
  • [35] Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis
    Honda, Akira
    Tanaka, Atsushi
    Komori, Atsumasa
    Abe, Masanori
    Inao, Mie
    Mochida, Satoshi
    Namisaki, Tadashi
    Yoshiji, Hitoshi
    Hashimoto, Naoaki
    Kawata, Kazuhito
    Takahashi, Atsushi
    Ohira, Hiromasa
    Kang, Jong-Hon
    Yamagiwa, Satoshi
    Joshita, Satoru
    Umemura, Takeji
    Sato, Ken
    Itakura, Jun
    Kaneko, Akira
    Kakisaka, Keisuke
    Takikawa, Yasuhiro
    Kikuchi, Kentaro
    Takikawa, Hajime
    Matsuzaki, Yasushi
    HEPATOLOGY, 2017, 66 : 42A - 43A
  • [36] Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score
    Hegade, Vinod S.
    Khanna, Amardeep
    Walker, Lucy J.
    Wong, Lin-Lee
    Dyson, Jessica K.
    Jones, David E. J.
    DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (10) : 3037 - 3044
  • [37] Good long-term outcomes of primary sclerosing cholangitis in childhood
    Skarby, Anna Jerregard
    Casswall, Thomas
    Bergquist, Annika
    Lindstrom, Lina
    JHEP REPORTS, 2024, 6 (08)
  • [38] Long-term outcomes of liver transplantation for primary sclerosing cholangitis
    Harputluoglu, M. M.
    Calgin, M. Z.
    Bilgic, Y.
    Kutlu, R.
    Yilmaz, S.
    TRANSPLANTATION, 2022, 106 (8S) : 193 - 193
  • [39] Management of symptom complexes in primary biliary cholangitis
    Kuo, Alexander
    Kuo, Alexander
    Bowlus, Christopher L.
    CURRENT OPINION IN GASTROENTEROLOGY, 2016, 32 (03) : 204 - 209
  • [40] Pathogenesis and management of fatigue in primary biliary cholangitis
    Shamshtein, Dana
    Liwinski, Timur
    FATIGUE-BIOMEDICINE HEALTH AND BEHAVIOR, 2022, 10 (01): : 1 - 25